- Home
- » Tags
- » Dapagliflozin
Top View
- Glenmark Receives Approval for Combination of Remogliflozin Etabonate and Metformin Hydrochloride for Adults with Type 2 Diabetes in India
- Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice
- ERX.NPA.136 Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
- Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes
- SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
- Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus
- The Effects of SGLT2 Inhibitors on Lipid Metabolism
- Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
- QTERN (Dapagliflozin and Saxagliptin) Is Indicated As an Adjunct to Diet and Exercise to Improve Glycemic Control in Adults with Type 2 Diabetes Mellitus
- Adverse Effects and Safety of SGLT2 Inhibitor Use Among Patients with Type 2 Diabetes: Findings from RCT Evidence
- Dapagliflozin and Metformin
- DAPA-HF: Dapagliflozin Versus Placebo in Patients with Heart Failure & Reduced EF 1 Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
- Assessment of Dapagliflozin Effectiveness As Add-On Therapy
- Xigduo, INN-Dapagliflozin and Metformin
- Comparison of Dapagliflozin
- Dapagliflozin/Metformin Immediate-Release Tablets
- XIGDUO XR (Dapagliflozin and Metformin Hcl Extended-Release)
- Dapagliflozin Improves Glycemic Control And
- Qtern (Dapagliflozin, Saxagliptin)
- FARXIGA Safely and Effectively
- Effects of Dapagliflozin And/Or Insulin Glargine on Beta Cell Mass And
- Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes Under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
- Sodium Glucose Co Transporter 2 (SGLT2) Inhibitors: a New Sword for the Treatment of Type 2 Diabetes Mellitus
- The VERTIS CV Trial
- (Qtern), Dapagliflozin/Saxagliptin/Metformin (Qternmet
- Product Monograph Including Patient Medication Information
- Diabetes Medications Timeline of Insulin Therapies in the US
- To Compare the Efficacy of Dapagliflozin & Metformin Vs
- 5.01.569 Pharmacotherapy of Type I and Type II Diabetes Mellitus
- FARXIGA (Dapagliflozin) Is Indicated
- Step Therapy
- Dapagliflozin for the Treatment of Heart Failure with Reduced Ejection Fraction
- SGLT2 Inhibitors
- SGLT2 Inhibitors: a Review of Their Antidiabetic and Cardioprotective Effects
- Dapagliflozin Is Effective As Add-On Therapy To
- Dapagliflozin) Tablets, for Oral Use Monitor Renal Function During Therapy
- Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes
- SGLT2 Inhibitors and Risk of Genitourinary Infections
- Dapagliflozin (Forxiga) for Type 1 Diabetes Mellitus – Add-On to Insulin Therapy
- Commissioning Support Dapagliflozin (Forxiga® )
- Quartz Drug Formulary: RX Outcomes List
- Medications for Hyperglycemia in Type 2 Diabetes and Review of Insulin Degludec and Dapagliflozin
- Canagliflozin, Dapagliflozin and Empagliflozin As Monotherapies for Treating Type 2 Diabetes
- DPP-4 Inhibitors Vs. SGLT-2 Inhibitors; Cons and Pros Xourgia E, Papazafiropoulou AK*, Karampousli E and Melidonis A
- SGLT2 STEP POLICY Farxiga (Dapagliflozin), Glyxambi
- Dapagliflozin, Saxagliptin, and Metformin
- 5.01.569 Pharmacotherapy of Type I and Type II Diabetes Mellitus
- Sodium Glucose Co-Transporter Type 2 (SGLT2) Inhibitors – Moving Beyond Targets
- Online-Only Supplemental Material
- Assessment of Remogliflozin Etabonate, a Sodium-Dependent
- Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
- Qtern, INN-Saxagliptin and Dapagliflozin
- Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR)
- Glenmark Launches Novel, Globally-Researched Anti-Diabetes Drug Remogliflozin in India
- QTERNMET XR Safely and Effectively
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- Possibility of Pharmacokinetic Drug Interaction Between a DPP-4 Inhibitor and a SGLT2 Inhibitor
- Downloaded the Glucose Data from the Sensor and Used Dose of Metformin As Covariates (As Described Above), Dedicated Software for Analysis (Abbott Diabetes Care)